Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Tandem Diabetes Care $316.25 million convertible senior notes offering
The 1.5% convertible senior notes are due 2029
LivaNova $345 million convertible notes offering and capped call transactions
The 2.5% convertible senior notes are due 2029
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cardinal Health $1.15 billion notes offering
The investment-grade notes are due 2029 and 2034
Prime Medicine $161 million stock and pre-funded warrants offering
The common stock is listed on the Nasdaq Global Market
Cigna $4.5 billion senior notes offering
The senior notes are due 2029, 2031, 2034 and 2054
Novo Nordisk class certification victory
The district court denied plaintiffs’ motion for class certification in its entirety
Metagenomi $93.75 million IPO
The shares are listed on the Nasdaq Global Market
Tenaya Therapeutics $50 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market